Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 12:38 PM
Ignite Modification Date:
2025-12-24 @ 12:38 PM
NCT ID:
NCT02934061
Brief Summary:
Open label, randomized, controlled, multicenter study with two parallel groups of patients
Detailed Description:
This is a phase III, open label, randomized, controlled, multicenter study with two parallel groups of patients.
Tizaspray® 0.5 mg (a new pharmaceutical form, liquid nasal spray solution), is proposed in this trial as a ready to use treatment for short term therapy of painful muscle spasms as the acute low back pain.
Study:
NCT02934061
Study Brief:
Protocol Section:
NCT02934061